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En bloc radical vulvectomy with bilateral inguinofemoral lymphadenectomy has now been replaced by radical wide excision and
selective inguinal lymphadenectomy based on the stage and location of invasive vulvar cancer. Early stage lateral cancers can be
effectively treated by radical wide excision and ipsilateral superficial inguinal lymphadenectomy. Lymph node mapping using
perilesional injection of radiocolloid and blue dye may identify sentinel lymph nodes which can be removed, thereby avoiding the
morbidity of full inguinal lymphadenectomy in selected patients with early stage disease.
1. Introduction
Although squamous cell carcinoma of the vulva is not com-
mon, it is occurring with increasing frequency in younger
women, particularly in those exposed to human papilloma
virus (HPV). With efforts at education, many patients are
presenting with early stage disease which is amenable to
surgery. This year, there will be approximately 3500 new
cases of vulvar cancer in the United States, representing 5%
of all gynecologic cancers [1]. The surgical management of
this disease has evolved from en bloc resection of the entire
vulva with bilateral superficial and deep inguinofemoral lym-
phadenectomy to a more conservative approach involving
radical wide excision of the primary lesion and specific
types of inguinal lymphadenectomy based on the stage and
anatomic location of disease.
2. Anatomic Pathways of Spread and Staging
The lymphatic drainage of the vulva has been studied
extensively and described in numerous publications [2, 3].
Generally, lateralizing lesions (>1 cm beyond the midline)
drain to the ipsilateral superficial inguinal lymph nodes,
whereas midline lesions can drain to either side (Figure 1).
It is extremely rare for lateralizing vulvar cancers to spread to
the contralateral inguinal lymph nodes if there is no evidence
of ipsilateral lymph node metastases. Likewise, it is unusual
for the deep inguinal nodes (below the cribriform fascia) to
be involved in the absence of superficial inguinal lymph node
spread. The current International Federation of Gynecology
and Obstetrics Staging System for vulvar cancer is now based
on surgical findings as illustrated in Table 1 and reflects the
extent and location of inguinal lymph node metastases.
3. Surgery of the Primary Vulvar Lesion
The Basset-Way operation which was the standard of care
in the operative management of patients with vulvar cancer
included the en bloc resection of the primary lesion and
surrounding vulvar skin as well as the skin over both groins
(Figure 2(a)) [4]. Although this procedure was curative in
the majority of cases, the wound defect was significant
and incisional breakdown and lymphedema of both lower
extremities were common. Currently, the surgical treatment
of vulvar cancer involves radical wide excision of the primary
lesion and inguinal lymphadenectomy through separate
groin incisions (Figure 2(b)) [5]. Heaps and colleagues [6]
reported that local control of vulvar cancers could be
achieved in 100% of cases provided that a 1 cm margin of
normal skin was included in the surgical specimen. These
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Figure 1: Lateral vulvar lesions >1 cm from the midline (a) spread initially to the ipsilateral superficial inguinal lymph nodes, whereas
midline lesions can spread to both groins (b).
(a) (b)
Figure 2: The Bassett-Way operation includes en bloc radical resection of the primary lesion and surrounding vulvar skin as well as the skin
over both groins (a). Radical wide excision of the vulvar cancer includes a margin of at least 1 cm of normal skin around the entire lesion.
Inguinal lymphadenectomy is performed through separate groin incisions (b).
observations were confirmed by De Hullu and coworkers [7]
who reported that there was no local recurrence of T1 or
T2 vulvar cancers when a margin of at least 8mm normal
skin was excised with the primary lesion. In contrast, patients
with a margin of <8mm had a local recurrence rate of 22%.
At present, it is recommended that a margin of at least 1 cm
of normal skin around the circumference of the primary
vulvar lesion be included in the surgical specimen and that
the underlying subcutaneous tissue be removed to the level
of the perineal fascia. Inguinal lymphadenectomy is then
performed through separate incisions.
4. Sentinel Lymphadenectomy
Sentinel lymph node excision is now being recommended in
selected patients with early stage squamous cell carcinoma
as a means to avoid the operative morbidity associated with
inguinofemoral lymphadenectomy [8–10]. It is estimated
that only 25–30% of patients with early stage vulvar cancer
have lymph node metastases, and complete inguinofemoral
lymphadenectomy is associated with postoperative wound
complications and lower extremity edema in 30–40% of
patients [11]. Sentinel lymph node mapping using radio-
labelled ultrafiltered sulfur colloid was initially reported as
a method to identify regional lymph node metastases in
breast cancer [12, 13] and cutaneous melanoma [4] and has
now been evaluated in patients with early stage vulvar cancer.
Specifically, 1-2mCi of radiocolloid is injected intradermally
around the lesion (Figure 3), and a hand held gamma
detection device is used to identify the sentinel lymph
node(s). Recently, lymphoscintigraphy has been combined
with intraoperative perilesional injection of isosulfan blue
as a method to identify sentinel nodes in the inguinal area.
Localization of the sentinel node(s) is usually apparent 5–15
minutes after injection of blue dye and 30minutes after injec-
tion of radiocolloid. Selman and colleagues [14] performed
a systematic review of the accuracy of sentinel lymph node
detection in identifying inguinal lymph node metastases in
vulvar cancer and reported that the combination of 99mTc
radiocolloid and isosulfan blue dye successfully detected
sentinel lymph nodes in 97% of cases. It also had a negative
predictive value (NPV) of 99.1%. Further analysis has
indicated that sentinel lymph nodemapping is most accurate
in patients with early stage lateral vulvar cancers [15].
A persisting concern about sentinel lymph nodemapping
in vulvar cancer is the frequency of groin recurrences in
patients with negative sentinel lymph nodes. In a multi-
institutional observational study, Van Der Zee and coworkers
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Table 1: FIGO staging of invasive cancer of the vulva.
Stage I Tumor confined to the vulva
IA
Lesions ≤2 cm in size confined to the vulva or
perineum and with stromal invasion ≤1.0mm∗,
no nodal metastasis
IB
Lesions >2 cm in size confined to the vulva or
perineum with stromal invasion greater than 1.0mm∗,
no nodal metastasis
Stage II
Tumor of any size with extension to adjacent perineal
structures (1/3 lower urethra, 1/3 lower vagina, anus),
no nodal metastasis
Stage III
Tumor of any size with or without extension to adjacent
perineal structures (1/3 lower urethra, 1/3 lower vagina,
anus) with positive inguinofemoral lymph nodes
IIIA With 1 lymph node metastasis (≥5mm),
IIIB
(i) With 2 or more lymph node metastases (≥5mm),
(ii) 3 or more lymph node metastases (<5mm)
IIIC With positive nodes with extracapsular spread
Stage IV
Tumor invades other regional (2/3 upper urethra, 2/3
upper vagina) or distant structures
IVA
Tumor invades any of the following:
(i) Upper urethra and/or vaginal mucosa, bladder
mucosa, rectal mucosa, or fixed to pelvic bone,
(ii) Fixed or ulcerated inguinofemoral lymph nodes
IVB Any distant metastasis including pelvic lymph nodes
∗
The depth of invasion is defined as the measurement of the tumor from the
epithelial-stromal junction of the adjacent most superficial dermal papilla to
the deepest point of invasion.
Figure 3: Sentinel lymph node mapping. Sentinel lymph nodes
are localized by perilesional injection of 99mTc radiocolloid and
isosulfan blue dye.
[10] performed the sentinel node procedure in 623 groins of
403 assessable patients. Two hundred fifty-nine patients with
unifocal vulvar cancers <4 cm diameter and negative sentinel
nodes were followed without additional therapy for a median
of 35 months. Six groin recurrences (2.3%) were observed,
and the 3-year survival of these patients was 97%. Impor-
tantly, both short-term morbidity and long-term morbidity
of patients having sentinel node excision were significantly
reduced when compared to that of women undergoing
complete inguinofemoral lymphadenectomy. These authors
concluded that sentinel node dissection, performed by a
quality-controlled multidisciplinary team, should be offered
to selected patients with early stage vulvar cancer as a
means to avoid the postoperative morbidity associated with
inguinofemoral lymphadenectomy.
There is a definite learning curve in the performance
and interpretation of lymph node mapping, and it is
recommended that a multidisciplinary group within each
institution perform sentinel node mapping in at least 10–
20 cases before it becomes an accepted procedure [10, 16].
If sentinel lymph nodes cannot be identified by mapping or
if there is uncertainty concerning interpretation of findings, a
superficial inguinal lymphadenectomy should be performed.
Patients with a positive sentinel node should undergo a
full inguinofemoral lymphadenectomy followed by postop-
erative radiation therapy to the involved groin and pelvis.
However, if the sentinel lymph nodes identified by mapping
are histologically negative after review by an experienced
multidisciplinary team, no further treatment is indicated.
It should be emphasized that optimal candidates for sen-
tinel lymph nodemapping are patients who have lateral T1 or
T2 unifocal vulvar cancers <4 cm diameter with nonpalpable
groin nodes [10]. This procedure is less accurate in patients
with midline vulvar lesions or those with advanced stage
disease and clinically palpable inguinal nodes [17].
5. Superficial Inguinal Lymphadenectomy
Many surgeons concerned about the accuracy of sentinel
lymph mapping have elected to perform superficial inguinal
lymphadenectomy as the treatment of choice in patients
with early stage vulvar cancer, believing that the superficial
inguinal nodes are themselves “sentinel nodes.” Specifically,
all inguinal lymph nodes above the cribriform fascia are
removed en bloc (Figure 4). Approximately 8–10 lymph
nodes are excised, and the saphenous vein is preserved
in order to decrease the frequency of postoperative lower
extremity lymphedema [18, 19]. Berman and coworkers
[20] reported the outcomes of 50 patients with T1 vulvar
cancers <1 cm diameter with stromal invasion >5mm who
underwent radical wide excision and superficial inguinal
lymphadenectomy. Women with positive superficial inguinal
nodes underwent deep inguinal lymphadenectomy and
radiation, whereas patients with negative superficial inguinal
nodes received no further treatment. There were no isolated
groin recurrences noted during a follow-up period of 36
months. Importantly, only 1 patient died of recurrent
cancer, and wound complications were observed in only
12% of patients. These authors concluded that radical wide
excision of the primary lesion and superficial inguinal
lymphadenectomy was the treatment of choice for most
women with early stage vulvar cancer and no evidence of
enlarged inguinal lymph nodes on clinical examination. A
persisting concern of this approach has been a significant
but low incidence of groin recurrence in patients with
negative superficial inguinal lymph nodes at the time of
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Figure 4: Radical wide excision and ipsilateral superficial inguinal
lymphadenectomy is performed for lateral T1 or T2 vulvar cancers.
All lymph nodes above the cribriform fascia are removed and the
saphenous vein is preserved.
lymphadenectomy. Two investigators have reported a 4–
7% incidence of subsequent ipsilateral groin failure after
negative primary superficial groin dissection [21, 22]. This
is worrisome since the majority of patients with groin
recurrence died of their disease. However, these studies were
retrospective and in one series [21] the anatomic location
of the primary vulvar lesion was not reported. In the most
recent investigation [22], vulvar cancers that recurred in the
groin after negative superficial inguinal lymphadenectomy
were central periclitoral lesions and the number of lymph
nodes removed was small (∼3 per groin). Therefore, these
authors recommend superficial inguinal lymphadenectomy
as the initial surgical approach in patients with lateral Stage I
or Stage II vulvar cancers provided that an adequate number
of superficial inguinal lymph nodes (8–10) are removed [22].
Currently, superficial inguinal lymphadenectomy should be
considered only in patients with lateral T1 and T2 vulvar
cancers having >1mm stromal invasion and no clinical
evidence of enlarged groin nodes.
6. Deep Inguinal Lymphadenectomy
Anatomic studies have indicated that some superficial
inguinal nodes may be located within the interstices of the
cribriform fascia and could be missed by purely superficial
inguinal lymphadenectomy [23]. Therefore, some surgeons
choose to perform deep inguinal lymphadenectomy rou-
tinely at the time of superficial inguinal lymphadenectomy.
The deep femoral lymph nodes are always located within
the opening of the fossa ovalis medial to the femoral vein,
and no lymph nodes are distal to the lower margin of the
fossa ovalis or lateral to the femoral vein (Figure 5). For this
reason, incision of the deep fascia of the adductor canal and
dissection of the femoral vessels, sometimes performed as
part of this procedure, are unnecessary. This is important
since deep fascial incision and stripping of the femoral
vessels is associated with postoperative wound breakdown,
lymphocyst formation, and lower extremity edema in up to
40% of cases [11, 24].
Figure 5: Radical wide excision and bilateral inguinofemoral
lymphadenectomy is performed for midline vulvar cancers. This
illustration depicts the right superficial inguinal lymph nodes and
the left deep femoral lymph nodes which are seen along the medial
aspect of the fossa ovalis.
At one time, patients with positive superficial or deep
inguinal nodes were treated by pelvic lymphadenectomy.
However, a prospective trial conducted by the Gynecologic
Oncology Group showed that patients with inguinal lymph
node metastasis at the time of groin dissection who were
treated by postoperative inguinal and pelvic radiation had
a significant survival advantage when compared to similar
patients treated by pelvic lymphadenectomy [25]. Patients in
the radiation therapy arm received 45–50Gy to the involved
groin and pelvis, whereas patients randomized to pelvic
lymphadenectomy underwent a standard extraperitoneal
excision of the obturator, external iliac, internal iliac, and
common iliac lymph nodes. This trial showed a statistically
significant survival advantage to patients in the radiation
therapy arm (68% versus 54% observed survival) on interim
analysis [26]. Therefore, most vulvar cancer patients with
positive superficial or deep inguinal lymph node metas-
tases at the time of inguinal lymphadenectomy are treated
now by postoperative radiation to the involved groin and
pelvis.
7. Unilateral versus Bilateral
Inguinal Lymphadenectomy
Anatomic studies have confirmed that efferent lymphatics
from the lateral vulva drain initially to the ipsilateral
superficial inguinal lymph nodes [2, 27]. Likewise, lateral
vulvar cancers (>1 cm beyond the midline) do not spread
to the contralateral inguinal lymph nodes without first
involving the ipsilateral inguinal nodes [27, 28]. These
anatomic observations have led to clinical trials evaluating
the efficacy of radical wide excision and ipsilateral inguinal
lymphadenectomy in the treatment of lateral vulvar cancers.
DeSimone and coworkers [29], for example, treated 122
patients with lateral T1 or T2 vulvar cancers by radical
vulvectomy (N = 60) or radical wide excision (N = 62)
and bilateral inguinal lymphadenectomy. Twenty-six patients
(21%) had ipsilateral inguinal lymph node metastases, but
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there were no cases of spread to the contralateral inguinal
lymph nodes. Patients with positive inguinal nodes were
treated by postoperative radiation therapy to the involved
groin and pelvis. All patients in the study were followed
periodically by clinical examinations 10–195 months (mean
59 months) after treatment. Eighteen patients (15%) devel-
oped recurrent vulvar cancer—13 to the ipsilateral vulvar
skin, 2 to the ipsilateral groin, and 3 to the lung. There
were no recurrences to the contralateral vulvar skin or groin.
Likewise, there was no difference in the local recurrence rate
of patients treated by radical vulvectomy versus those treated
by radical wide excision. The 5-year disease-free survival was
98% for patients with T1 lesions and 93% for patients with T2
lesions. These authors concluded that women with lateral T1
and T2 vulvar cancers could be treated effectively by radical
wide excision and ipsilateral inguinal lymphadenectomy.
There is still some controversy concerning the per-
formance of routine contralateral inguinofemoral lym-
phadenectomy in patients with lateral vulvar cancers and
positive ipsilateral inguinal nodes. Isolated reports have
indicated that contralateral inguinal lymph node metastases
can occur in these patients. However, the frequency of
contralateral spread in these patients is extremely low, and
the risk of contralateral inguinal lymphadenectomy may
outweigh its benefits, particularly if only a small number of
ipsilateral nodes are positive.
All vulvar cancers located within 1 cm of midline struc-
tures (clitoris, vagina, or anus) have the potential to spread
to both groins, and should be treated by radical wide excision
and bilateral inguinofemoral lymphadenectomy.
8. Summary
The Bassett-Way operation, which emphasized en bloc
resection of the vulva and both groins, has been replaced
by radical wide excision and selective inguinal lymphadenec-
tomy through separate groin incisions. The specific type of
inguinal lymphadenectomy indicated depends on the stage
and location of each cancer. Early stage lateral vulvar cancers
can be treated safely by radical wide excision and ipsilat-
eral superficial inguinal lymphadenectomy, whereas central
vulvar cancers require bilateral inguinal lymphadenectomy.
Deep inguinal lymphadenectomy, which involves surgical
removal of the deep femoral nodes, is indicated in patients
with centrally located early stage vulvar cancers, advanced
stage vulvar cancers, and in patients with positive superficial
inguinal lymph nodes. The deep femoral lymph nodes
are always located medial to the femoral vein and can
be removed without incising the deep fascia or dissecting
the femoral vessels. Sentinel lymph node mapping should
be offered to select patients with early stage lateral vulvar
cancers as a means to avoid the postoperative morbidity
associated with full inguinofemoral lymphadenectomy.
References
[1] A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun,
“Cancer statistics, 2009,”CA: Cancer Journal for Clinicians, vol.
59, no. 4, pp. 225–249, 2009.
[2] A. A. Plentl and E. A. Friedman, Lymphatic System of the
Female Genitalia: The Morphologic Basis of Oncologic Diagnosis
and Therapy, Saunders, Philadelphia, Pa, USA, 1971.
[3] D. C. Figge, H. K. Tamimi, and B. E. Greer, “Lymphatic spread
in carcinoma of the vulva,” American Journal of Obstetrics and
Gynecology, vol. 152, no. 4, pp. 387–394, 1985.
[4] S. Way, “Carcinoma of the vulva,” American Journal of
Obstetrics and Gynecology, vol. 79, pp. 692–697, 1960.
[5] N. F. Hacker, R. S. Leuchter, J. S. Berek, T. W. Castaldo, and L.
D. Lagasse, “Radical vulvectomy and bilateral inguinal lym-
phadenectomy through separate groin incisions,” Obstetrics
and Gynecology, vol. 58, no. 5, pp. 574–579, 1981.
[6] J. M. Heaps, Y. S. Fu, F. J. Montz, N. F. Hacker, and J. S. Berek,
“Surgical-pathologic variables predictive of local recurrence in
squamous cell carcinoma of the vulva,” Gynecologic Oncology,
vol. 38, no. 3, pp. 309–314, 1990.
[7] J. A. De Hullu, H. Hollema, S. Lolkema et al., “Vulvar
carcinoma: the price of less radical surgery,” Cancer, vol. 95,
no. 11, pp. 2331–2338, 2002.
[8] J. A. De Hullu, H. Hollema, D. A. Piers et al., “Sentinel lymph
node procedure is highly accurate squamous cell carcinoma
of the vulva,” Journal of Clinical Oncology, vol. 18, no. 15, pp.
2811–2816, 2000.
[9] R. G. Moore, K. Robison, A. K. Brown et al., “Isolated sentinel
lymph node dissection with conservative management in
patients with squamous cell carcinoma of the vulva: a
prospective trial,” Gynecologic Oncology, vol. 109, no. 1, pp.
65–70, 2008.
[10] A. G. J. Van Der Zee, M. H. Oonk, J. A. De Hullu et al.,
“Sentinel node dissection is safe in the treatment of early-stage
vulvar cancer,” Journal of Clinical Oncology, vol. 26, no. 6, pp.
884–889, 2008.
[11] K. N. Gaarenstroom, G. G. Kenter, J. B. Trimbos et al., “Post-
operative complications after vulvectomy and inguinofemoral
lymphadenectomy using separate groin incisions,” Interna-
tional Journal of Gynecological Cancer, vol. 13, no. 4, pp. 522–
527, 2003.
[12] T. Kim, A. E. Giuliano, and G. H. Lyman, “Lymphatic
mapping and sentinel lymph node biopsy in early-stage breast
carcinoma: a metaanalysis,” Cancer, vol. 106, no. 1, pp. 4–16,
2006.
[13] R. E. Mansel, L. Fallowfield, M. Kissin et al., “Randomized
multicenter trial of sentinel node biopsy versus standard
axillary treatment in operable breast cancer: the ALMANAC
trial,” Journal of the National Cancer Institute, vol. 98, no. 9,
pp. 599–609, 2006.
[14] T. J. Selman, D. M. Luesley, N. Acheson, K. S. Khan, and C. H.
Mann, “A systematic review of the accuracy of diagnostic tests
for inguinal lymph node status in vulvar cancer,” Gynecologic
Oncology, vol. 99, no. 1, pp. 206–214, 2005.
[15] C. Louis-Sylvestre, E. Evangelista, F. Leonard, E. Itti, M.
Meignan, and B. J. Paniel, “Sentinel node localization should
be interpreted with caution in midline vulvar cancer,” Gyneco-
logic Oncology, vol. 97, no. 1, pp. 151–154, 2005.
[16] C. F. Levenback, “How safe is sentinel lymph node biopsy in
patients with vulvar cancer?” Journal of Clinical Oncology, vol.
26, no. 6, pp. 828–829, 2008.
[17] M. Frumovitz, P. T. Ramirez, G. Tortolero-Luna et al.,
“Characteristics of recurrence in patients who underwent
lymphatic mapping for vulvar cancer,” Gynecologic Oncology,
vol. 92, no. 1, pp. 205–210, 2004.
[18] S. C. Plaxe, P. S. Braly, and P. R. Dottino, “A simplified
approach to superficial inguinal dissection with sparing of
the saphenous vein in patients with carcinoma of the vulva,”
6 International Journal of Surgical Oncology
Surgery Gynecology and Obstetrics, vol. 176, no. 3, pp. 295–296,
1993.
[19] S. H. Zhang, A. K. Sood, J. I. Sorosky, B. Anderson, and
R. E. Buller, “Preservation of the saphenous vein during
inguinal lymphadenectomy decreases morbidity in patients
with carcinoma of the vulva,” Cancer, vol. 89, no. 7, pp. 1520–
1525, 2000.
[20] M. L. Berman, J. T. Soper, W. T. Creasman, G. T. Olt, and P.
J. SiSaia, “Conservative surgical management of superficially
invasive stage I vulvar carcinoma,” Gynecologic Oncology, vol.
35, no. 3, pp. 352–357, 1989.
[21] M. E. Gordinier, A. Malpica, T. W. Burke et al., “Groin
recurrence in patients with vulvar cancer with negative
nodes on superficial inguinal lymphadenectomy,” Gynecologic
Oncology, vol. 90, no. 3, pp. 625–628, 2003.
[22] T. O. Kirby, R. P. Rocconi, T. M. Numnum et al., “Outcomes
of stage I/II vulvar cancer patients after negative superficial
inguinal lymphadenectomy,” Gynecologic Oncology, vol. 98,
no. 2, pp. 309–312, 2005.
[23] C. N. Hudson, H. Shulver, and D. C. Lowe, “The surgery of
’inguino-femoral’ lymph nodes: is it adequate or excessive?”
International Journal of Gynecological Cancer, vol. 14, no. 5, pp.
841–845, 2004.
[24] N. Gould, S. Kamelle, T. Tillmanns et al., “Predictors of
complications after inguinal lymphadenectomy,” Gynecologic
Oncology, vol. 82, no. 2, pp. 329–332, 2001.
[25] F. B. Stehman, B. N. Bundy, G. Thomas et al., “Groin
dissection versus groin radiation in carcinoma of the vulva: a
Gynecologic Oncology Group study,” International Journal of
Radiation Oncology Biology Physics, vol. 24, no. 2, pp. 389–396,
1992.
[26] C. Kunos, F. Simpkins,H. Gibbons, C. Tian, and H. Homesley,
“Radiation therapy compared with pelvic node resection for
node-positive vulvar cancer: a randomized controlled trial,”
Obstetrics and Gynecology, vol. 114, no. 3, pp. 537–546, 2009.
[27] H. D. Homesley, B. N. Bundy, A. Sedlis et al., “Assess-
ment of current International Federation of Gynecology and
Obstetrics staging of vulvar carcinoma relative to prognostic
factors for survival (A Gynecologic Oncology Group Study),”
American Journal of Obstetrics and Gynecology, vol. 164, no. 4,
pp. 997–1004, 1991.
[28] S. J. Andrews, B. T.Williams, P. D. DePriest et al., “Therapeutic
implications of lymph nodal spread in lateral T1 and T2
squamous cell carcinoma of the vulva,” Gynecologic Oncology,
vol. 55, no. 1, pp. 41–46, 1994.
[29] C. P. DeSimone, J. S. Van Ness, A. L. Cooper et al., “The
treatment of lateral T1 and T2 squamous cell carcinomas of
the vulva confined to the labiummajus or minus,” Gynecologic
Oncology, vol. 104, no. 2, pp. 390–395, 2007.
Submit your manuscripts at
http://www.hindawi.com
Stem Cells
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Behavioural 
Neurology
Endocrinology
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Disease Markers
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Oncology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Oxidative Medicine and 
Cellular Longevity
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
PPAR Research
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Immunology Research
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Obesity
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Computational and  
Mathematical Methods 
in Medicine
Ophthalmology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Diabetes Research
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Research and Treatment
AIDS
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Gastroenterology 
Research and Practice
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Parkinson’s 
Disease
Evidence-Based 
Complementary and 
Alternative Medicine
Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
